



**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group**

**Summary of Main Points from the Meeting held on
Monday 11th November 2024**

2. Minutes and Summary Notes from last meeting

This meeting was held via Teams. The Minutes and Summary notes of the Medicines Group Meeting held on 16th September 2024 were approved. The summary notes will be disseminated and published on the Trust intranet. A quarterly summary report will be drafted and forwarded to the Trust Patient Safety Group meeting for inclusion on the agenda in due course.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

4.1 Formulary Applications

Full Applications

• **Aztreonam 1g and 2g Infusion**

Requested by: Microbiology

Indication: Treatment of metallo beta-lactamase class carbapenemase producing Enterobacterales and Pseudomonas infections

Proposal: Add to the formulary in line with licensed indication

Cost: £45 per patient per day

Likely to treat: 12-18 patients per year across both hospital sites

Outcome: Approved for addition to the Trust Formulary

• **Aztreonam/Avibactam 1.5g/0.5g Infusion (Emblaveo®)**

Requested by: Microbiology

Indication: Treatment of metallo beta-lactamase class carbapenemase producing Enterobacterales and Pseudomonas infections

Proposal: Add to the formulary in line with licensed indication

Cost: Up to £720 per patient per day

Likely to treat: 12-18 patients per year across both hospital sites

There was an extended discussion regarding the clinical need to have this antibiotic option available on the Trust Formulary balanced with the significant cost to divisional drug budgets.

The Trust has seen an increasing number of complex infections due to the Class B metallo-beta-lactamases (MBLs) carbapenemase producing Enterobacterales. These are intrinsically resistant to most beta-lactams including meropenem, ceftazidime-avibactam, meropenem-relebactam and imipenem-relebactam. We currently treat these infections with either cefidericol or with a combination use of avibactam (as ceftazidime/avibactam which is currently on the Trust Formulary) plus aztreonam.

In September 2024, a new licensed product avibactam+aztreonam (0.5g/1.5g) intravenous solution has been introduced to the UK market (MHRA approved). This provides an alternative to using ceftazidime/avibactam with aztreonam for treatment of complex MDR infections. It eliminates the unnecessary administration and exposure to ceftazidime and its associated side effects. It was appreciated that use of this antibiotic would be challenging for drugs budgets but that it would be restricted to being initiated on Microbiology advice only

Outcome: Approved for addition to the Trust Formulary

Ex-Panel

• **Natalizumab 300mg Infusion (Tyruko®)**



Requested by: Neurology

Indication: Relapsing remitting Multiple Sclerosis in line with NICE guidance.

Proposal: Add to the formulary as a biosimilar for prescribing in place of originator: Natalizumab (Tysabri®)

Rational: Cost saving: £2k per person per year

Outcome: Approved for addition to the Trust Formulary

- **Ustekinumab 45mg, 90mg pre-filled syringes and 45mg, 130mg Infusion (Wezenla®)**

Requested by: Gastroenterology, Rheumatology and Dermatology

Indication: Crohn's Disease, Psoriatic Arthritis, Plaque Psoriasis in line with NICE guidance.

Proposal: Add to the formulary as a biosimilar for prescribing in place of originator: Ustekinumab (Stelara®)

Rational: Cost saving: £1.4k per dose

Outcome: Approved for addition to the Trust Formulary

Removals

- **Potassium Chloride 375mg/5ml (5mmol/5ml) Liquid (Kay-Cee-L®)**

Discontinued by the manufacturer

Remaining stock being restricted for Neonates use only.

Paediatrics to switch to using Sando K.

Outcome: Approved for removal from the Trust Formulary

NICE Approved drug applications

- **TA981 - Voxelotor for treating haemolytic anaemia caused by Sickle Cell Disease (12/06/2024)**

It was noted that subsequent to the NICE TA being published an imbalance in fatalities linked to vasomotor occlusion was identified and this drug was subsequently withdrawn from the UK market in September 2024.

Outcome: Voxelotor will not be added to the Trust Formulary

- **TA991 - Abaloparatide for treating osteoporosis after menopause (07/08/2024)**

Proposal: Add to the formulary in line with NICE TA991

Outcome: Approved for addition to the Trust Formulary

- **TA995 - Relugolix for treating hormone-sensitive prostate cancer (14/09/2024)**

Proposal: Add to the formulary in line with NICE TA995

Outcome: Approved for addition to the Trust Formulary

- **TA996 - Linzagolix for treating moderate to severe symptoms of uterine fibroids (14/08/2024)**

Proposal: Add to the formulary in line with NICE TA996

Outcome: Approved for addition to the Trust Formulary

- **TA999 - Vibegron for treating symptoms of overactive bladder syndrome (04/09/2024)**

Proposal: Add to the formulary in line with NICE TA999

Outcome: Approved for addition to the Trust Formulary

Pharmacoeconomic Board requests

- **Ustekinumab for Pyoderma Gangrenosum**

Approved by Pharmacoeconomic Board on 20/09/2024

Outcome: Noted

- **Palivizumab for RSV prophylaxis**

Approved by Pharmacoeconomic Board on 02/10/2024

Outcome: Noted

Other



- **Pirtobrutinib - FOC Scheme**

Approved by Pharmacoeconomic Board on 14/10/2024

Outcome: Noted

4.2 Trust Medicines Policy

- **TMP: Section 2 - Prescribing**

Updated in line with MHRA guidance relating to the Topiramate Pregnancy Prevention Programme

- New section added relating to Topiramate

Outcome: Approved

- **TMP: Section 3 - Ordering and supply of medicines**

- Routine review and update
- Removal of section relating to handwritten stock endorsements
- Removal of reference to paper in-patient prescriptions
- Addition of electronic requests for individually dispensed non-stock medicines for in-patients.
- Removal of reference to decanting strips of tablets/capsules from stock medicine packs
- Update of reference to Boots out-patient pharmacy to CW Medicines out-patient pharmacy
- Addition of a section relating to over-labelled or pre-packed medicines

Updated in line with MHRA guidance relating to the Topiramate pregnancy Prevention Programme

- New section added relating to Topiramate

Outcome: Approved

- **TMP: Section: 6. Controlled Drugs**

Routine review and update

- Removal of Oseltamavir and Zanamivir being treated as a controlled drugs within the Trust
- Update to Levobupivacaine epidural being a licensed product
- Removal of double checking being a Trust requirement on administration for oral Tramadol, Gabapentin and Pregabalin
- Addition on section relating to pharmacist amendments of CD prescriptions
- Frequency of stock checks in satellite pharmacies
- Addition of a section relating to storage of CDs that require fridge storage

Outcome: Approved

- **TMP: Section 16 - Ward/Department openings and closings**

Full review and update

- Update relating to location of returned ward CD keys at CWH Site

Outcome: Approved

- **TMP: Section 18 - Medical Representatives**

Full review and update

- Addition to reference to Early Access to Medicines Schemes.
- Addition of a section relating to Free of Charge Schemes

Outcome: Approved

- **TMP: Section 19 - The formulary**

Full review and update.

- Removal of the term "joint" in relation to the Trust Formulary
- Update of contact details for approval of urgent requests
- Addition of a section relating to the NWL ICB JFC
- Additional of the NWL ICB JFC application form
- Update to the sub-group name: Clinical Directorate of HIV, Sexual Health and Gender Health
- Inclusion of reference to NWL ICB JFC in Appendix 19.1



- Minor updates to the Application for the addition of a NICE approved medicine to the Trust Formulary
- Minor updates to the Non-formulary medicines request form

Outcome: Approved

- **TMP: Section 20. Unlicensed use of a licensed medicine**

Routine review and update

- Removal of a section relating to documentation retention for unlicensed medicines
- Removal of reference to EU regulations

Outcome: Approved

- **TMP: Section 30 - Supply of over-labelled/pre-packed medicines**

Full review and update

Addition of the following as a clinical areas that can operate in line with this policy:

- Eye clinic
- Plastic Dressing Clinic out-patient Suite 4
- Out-patient Clinic Gate 2

Addition of the following as a clinical areas off-site that can operate in line with this policy:

- NAZ charity Hammersmith and Fulham
- Old Oak Family Hub
- St Mungo's Hostels Hammersmith and Fulham
- Ted's Bar Hammersmith and Fulham
- The Villa
- Tudor Rose Family Hub
- Turning Point Hammersmith and Fulham

Pharmacy Technicians added to the list of healthcare professionals who can supply/administer medicines under PGD.

Removal of reference to Jupiter Ward

Outcome: Approved

- **Trust Medicines Policy Audit 2023**

Summary

CWH Site

Overall, the results showed that there is excellent compliance with the aspects of the Trust Medicines Policy for the majority of standards that were assessed in this audit.

- Of the 22 standards audited, it was possible to assess compliance to 21 standards. Of the 21 standards where it was possible to undertake an assessment of compliance, 95% (n=20) achieved 90% or greater compliance. A total of 13 (62%) standards scored 100% compliance.
- Of the 20 standards where variance in compliance from the 2021 audit could be assessed, the compliance either increased or remained static for 14 (70%) standards. Where the compliance remained static, 100% (n = 11) of these standards continued to have 100% compliance.
- Of the standards where variance in compliance from the 2021 audit decreased, 5 of 6 of these decreased marginally by <5%.
- There was one standard relating to the **documentation of warfarin indication, target INR range and INR results** that scored less than 80% compliance. This standard was also associated with a decrease in compliance of 25% compared with the 2021 audit results.



Results from this audit were collated as electronic medication charts only. Previous audits included results from paper and electronic drug charts. Since the 2021 audit, AEC and NICU have migrated from paper drug charts to electronic medication records.

Prescribing

Compliance to the prescribing standards remains high when compared with the 2021 audit results. This is a positive outcome as it demonstrates a high level of compliance when electronic prescribing is in place.

As regards the one standard relating to information being documented in relation to warfarin, where compliance was recorded to be <80%, the INR placeholder was not documented. However, it was documented in the patient's medication history that the patient was taking warfarin. Only 2 patients in total were identified in the audit who were taking warfarin, therefore with one patient not having the placeholder prescribed, due to the very small sample size, this resulted in a poor overall compliance of 75% to this particular standard.

Controlled Drugs and FP10 (HP) prescription

All standards relating to controlled drugs (CDs) and FP10 (HP) prescription scored 100% except for the standard relating to the documentation of CDs being destroyed on the ward which scored 95% compliance.

The standard relating to requisitions for concentrated IV potassium to named patients could not be audited as there were no issues to individual patients identified in the audit. This was due to IV potassium chloride being added to the CD stock list for Antenatal Clinic, which in previous years was the location which was associated with the highest number of named patient issues of this medication.

Medication errors and Missed doses

The standard relating to documentation of Missed doses scored less than 80% compliance in the 2021 audit, however this improved significantly in this audit with a compliance of 99%.

Audit Actions

Relating to warfarin Prescribing

- Pharmacists to be reminded of the need to ensure the Warfarin placeholder is added to the electronic medication record on Cerner when Warfarin is prescribed and to follow-up with the prescribing doctor if omitted.

Relating to IV Concentrated Potassium solutions

- Antenatal clinic to draft a Risk Assessment relating to the stocking of IV concentrated potassium solutions in the clinic.
- Seek approval of the Risk Assessment by the Trust Medication Safety Group
- Update Trust Medicines Policy - Section 24: Concentrated Potassium Solutions to include Antenatal Clinic being permitted to stock this concentrated IV potassium solutions
- Seek approval of the updated version of Trust Medicines Policy - Section 24: Concentrated Potassium Solutions by the Trust Medicines Group

All actions completed

WMUH Site

Overall, the results show that there is excellent compliance with most of the aspects of the Trust Medicines Policy for the majority of standards that were assessed in this audit.

- Of the 22 standards audited, it was possible to assess compliance with 20 standards. The standard relating to requisitions for concentrated IV potassium to named patients could not be audited as there were no issues to individual patients identified in the audit. Additionally, the standard relating to the storage of FP10(HP) prescriptions could not be audited as there are no clinical areas that hold a supply of FP10(HP) prescriptions.



- Of the 20 standards where it was possible to undertake an assessment of compliance, 100% (n=20) achieved 90% or greater compliance. A total of 18 (90%) standards scored 100% compliance.
- Of the 19 standards where variance in compliance from the 2021 audit could be assessed, the compliance either increased or remained static for 18 (95%) standards. Where the compliance remained static, 100% (n = 13) of these standards continued to have 100% compliance.
- There was 1 standard where compliance decreased by 1%.

Prescribing

Results from this audit were collated from electronic medication charts. The numbers of electronic charts used in the audit was determined by the proportion of hospital beds that operate with electronic medication charts. Migration from paper medication charts to Cerner EPMA took place on SCBU in October 2022. In addition, electronic out-patient, discharge, chemotherapy and AEC prescriptions were included and collectively provided a very accurate representation of compliance with the Medicines Policy across the hospital site and the effect that electronic prescribing has on compliance.

With electronic prescribing fully in place, compliance to the **Prescribing** standards continued to improve and achieved 100% compliance with all standards.

Controlled Drugs and FP10 (HP) prescription

Compliance to the Controlled drugs and FP10 (HP) prescription pads standards continued to improve when compared with the 2021 audit results.

It was identified that on one occasion, the recording of an issue of concentrated IV potassium chloride was made in the CD register however, the requisition number was not documented as part of the entry. As a result it would be prudent to ensure procedures are followed and staff are reminded of the information that needs to be recorded in the CD register on the dispensing of all controlled drugs.

Medication errors and Missed doses

Compliance to the standard relating to medication errors and missed doses, decreased by 1% compared with the 2021 audit. Missed doses are not being recorded consistently on Cerner EPR using the standard Trust codes on a number of wards. There is a trend of lower compliance to this particular standard since migration from paper medication charts to Cerner EPMA. The compliance to this standard was 98-100% when paper medication charts were in use and reduced to 93% when combined with compliance when electronic prescribing is in place. This issue continues to require ongoing addressing with support from the Trust Medication Safety Group.

Audit Actions

Relating to issue of controlled drugs

- Remind pharmacy staff the information that needs recording in the CD register including the requisition number.

Relating to missed doses

- Continue to have *Delayed and omitted doses of critical medicines* as a focal theme on the Medication Safety Group meeting agenda. Continue to ensure ongoing progress with the addressing of this issue across the Trust.

All actions completed

Outcome: Noted

4.3 Medicines Optimisation

Trust Medicines Optimisation Annual Report 2023-2024

Medicines optimisation encompasses a range of activities intended to improve the way that medicines are selected, procured, prescribed, dispensed and administered.



This report summarises the activities of groups responsible for the management of medicines at Chelsea and Westminster Hospital NHS Foundation Trust, describes developments throughout the 2023-24 year and reports on results of external assessments.

Summary

- Trust Medicines Group meetings x 5 held
- Formulary applications: 38 x applications - 8 x full submissions, 12 x ex-panel requests and 18 x Individual Funding Requests (approved by Pharmacoeconomic Board). All reviewed and approved
- Trust Medicines Policy: 12 x updates approved
- Other policies: 5 x new/updated approved
- NICE Technology Appraisals: 84 x NICE TAs noted and actioned of which 37 resulted in a formulary update.
- PGDs/NPs/WIs: 24 x PGDs, 3 x NPs and 1 x WI new/updated approved. By March 2023 there were 99 PGDs/NPs/WIs in use in the Trust.
- HIV:
 - Optimisation of HIV ARV therapy: 1,238 patients switched to more clinically appropriate or cost-effective regimens.
 - Support of MPox vaccination programme
 - Introduction of TransPlus service - Dedicated Senior and rotational pharmacist
 - Publications x 12
- Technical Services:
 - Continuation of service despite the production unit at CWH site being closed since March 2023. All SACT has been made at WMUH site.
- Antimicrobial Stewardship:
 - NHSE CQUINs 2023/24 goals met and exceeded.
 - NHS Contract requirements for reduced antimicrobial usage met and exceeded.
 - Real-time Antimicrobial Stewardship reviews of admitted patients with infection: > 20,000.
- VTE Prevention:
 - The Trust met achieve the national target of $\geq 95\%$ for VTE risk assessment completion for adult patients on admission to hospital in 2023-24.
 - 99% of adult patient at CWH site and 98% at WMUH site received appropriate pharmacological thromboprophylaxis
 - Guidelines x 16 updated; Audits 3 x undertaken; Publications x 6; Awards x 2
- Homecare:
 - As at March 2024, 3,773 patients enrolled and receiving medicines via Homecare services.
- Medication Safety:
 - A total of 1,925 medicine-related incidents reported across the Trust representing a 17% increase in incident reporting across both hospital sites.
 - Patient Safety Alerts x 13 actioned
 - Medication Safety Bulletins x 14 published
- Controlled Drugs:
 - Incidents related to CDs x 503 reviewed of which 111 related to unaccounted for CDs
 - of which 4 x incidents reported to NHS England; Staff related incidents x 2 concerning CDs were additionally escalated to NHS England.
- Non-Medical Prescribers:
 - By March 2024 there were 129 x NMPs in post and on the Trust NMP Register
- EPMA:
 - Virtual Wards pathway went live April 2023
 - Hillingdon Hospital went live with Cerner in November 2023
 - Prescribing support on Cerner developed for medicines with pregnancy prevention programmes in place
- Clinical Trials: Active Clinical Trials x 18 across both hospital sites
- Medicines related cost savings: £360k In-tariff; £133k Locally initiated
- Audit



- Clinical audits x 10 undertaken
- Trust medicines Policy Audit undertaken
- Medicines Information:
 - Enquiries received and managed x 919 (730 from HCPs and 189 from members of the public)
 - Publication x 1

This report will be sent to Patient Safety Group for noting.

Outcome: Noted

4.4 NICE Technical Appraisals and Guidance

13 x TA appraisals published since previous TMG meeting to November 2024

- TA997 Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (29/08/2024).
Formulary status / Action
Included on the formulary for another indication
Numbers likely to treat at CWH site: 1 patient per year
Numbers likely to treat at WMUH site: Nil patients per year
- TA998 Risankizumab for treating moderately to severely active ulcerative colitis (22/08/2024)
Formulary status / Action
Included on the formulary for another indication
Numbers likely to treat at CWH site: 10 patients per year
Numbers likely to treat at WMUH site: 10 patients per year
- TA999 Vibegron for treating symptoms of overactive bladder syndrome (04/09/2024)
Formulary status / Action
Not included on the formulary
Application form received - See Section 4.1
- TA1000 Iptacopan for treating paroxysmal nocturnal haemoglobinuria (04/09/2024)
Formulary status / Action
Not included on the formulary
Action: Not applicable to CWFT - Condition not treated at CWH and WMUH site
- TA1001 Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment (04/09/2024)
Formulary status / Action
Included on the formulary for another indication
Action: Confirm numbers likely to treat in line with this NICE TA
- TA1002 Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over (11/09/2024)
Formulary status / Action
Not included on the formulary
Action: N/A - CWFT not a commissioned site
- TA1003 Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over (11/09/2024)
Formulary status / Action
Not included on the formulary
Action: Not applicable to CWFT - Condition not treated at CWFT
- TA1004 Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion (11/09/2024)
Formulary status / Action
Included on the formulary for another indication



Numbers likely to treat at CWH site: 45 patients per year
Numbers likely to treat at WMUH site: N/A

- TA1005 Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (11/09/2024)

Formulary status / Action

Not included on the formulary

Action: Confirm if condition is treated at CWFT and agree appropriate action

TA1006 Empagliflozin for treating type 2 diabetes in people 10 to 17 years (Terminated appraisal) (12/09/2024)

Formulary status / Action

Nil - Terminated Appraisal

- TA1007 Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (17/09/2024)

Formulary status / Action

Not included on the formulary

Action: Not applicable to CWFT - Condition not treated at CWFT

- TA1008 Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments (25/09/2024)

Formulary status / Action

Included on the formulary for another indication

Numbers likely to treat at CWH site: 5-10 patients per year

Numbers likely to treat at WMUH site: 0 patients per year

- TA1009 Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension (02/10/2024)

Formulary status / Action

Not included on the formulary

Action: Add to the formulary following receipt of an application form from the Ophthalmology Department

b) NICE Highly Specialised Technology Appraisals published since last meeting

0 HST appraisal published since previous TMG meeting to November 2024

Action: Nil - Not applicable to CWFT

4.5 Items for noting

- **Quarterly Controlled Drug Summary Report - Q1 2024/25**

Quarterly Controlled Drug Summary Report for Q2 2024/25

Outcome: Noted

- **Quarterly Controlled Drugs Accountable Officer Report - Q1 2024/25**

Quarterly CD Accountable Officer Report for Q1 2024/25

Outcome: Noted

- **Non-Medical Prescribing Register - October 2024**

Trust Non-Medical Prescribing Register for October 2024

Outcome: Noted

- **Trust Patient Safety Group Report - October 2024**

Trust Medicines Report for Trust Patient Safety Report - October 2024

Outcome: Noted



- **Trust Quality Committee Report - November 2024**

Medicines Optimisation Report including Controlled Drugs and Medication Safety Q1 and Q2 2024/25 for Trust Quality Committee Report

Outcome: Noted

- **Medication Safety Bulletin: Cerner Medication Administration**

Medication Safety Bulletin relating to Cerner Medication Administration

Outcome: Noted

- **Medication Safety Bulletin: World Thrombosis Day**

Medication Safety Bulletin relating to World Thrombosis Day

Outcome: Noted

- **MHRA Drug Safety Update - September 2024**

MHRA update for September 2024

Outcome: Noted

- **MHRA Drug Safety Update - October 2024**

MHRA update for October 2024

Outcome: Noted

4.6 Meeting minutes for noting

- **NWL ICB Joint Formulary Committee Meeting Minutes - July 2024**

Minutes from NWL ICB Joint Formulary Committee Meeting held July 2024

Outcome: Noted

- **Antimicrobial Stewardship Group Meeting Minutes - May 2024**

Minutes from Antimicrobial Stewardship Group Meeting held May 2024

Outcome: Noted

- **Antimicrobial Stewardship Group Meeting Minutes - September 2024**

Minutes from Antimicrobial Stewardship Group Meeting held September 2024

Outcome: Noted

- **HIV, Sexual Health and Gender Health Medicines Sub-Group Meeting Minutes - July 2024**

Minutes from HIV, Sexual Health and Gender Health Medicines Sub-Group Meeting held September 2024

Outcome: Noted

- **HIV, Sexual Health and Gender Health Medicines Sub-Group Meeting Minutes - October 2024**

Minutes from HIV, Sexual Health and Gender Health Medicines Sub-Group Meeting held September 2024

Outcome: Noted

5. Any other business

Nil

6. Date of next meeting

Meetings Dates for 2025

Dates:

- All dates for 2025 - TBC

Time: 8am-9am

Location: via Teams